title: The biomarker landscape in mycosis fungoides and Sézary syndrome.
abstract: The practice of pre-emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicentre efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules.
authors.affiliation: Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA.
authors.forename: Brittany
authors.initials: B
authors.lastname: Dulmage
authors.affiliation: Department of Dermatology, Columbia University, New York, NY, USA.
authors.forename: Larisa
authors.initials: L
authors.lastname: Geskin
authors.affiliation: Department of Dermatology, Northwestern University, Chicago, IL, USA.
authors.forename: Joan
authors.initials: J
authors.lastname: Guitart
authors.affiliation: Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA.
authors.forename: Oleg E
authors.identifier: 0000-0003-1339-5710
authors.initials: OE
authors.lastname: Akilov
mesh_terms: D015415:Biomarkers / Q000097:blood*; D015870:Gene Expression; D006801:Humans; D009182:Mycosis Fungoides / Q000097:blood / Q000175:diagnosis*; D012751:Sezary Syndrome / Q000097:blood / Q000175:diagnosis*
chemical_list: D015415:Biomarkers
keywords: cell surface marker; cutaneous T-cell lymphoma; gene expression; screening; secretory protein